AR083786A1 - Compuestos antidiabeticos - Google Patents
Compuestos antidiabeticosInfo
- Publication number
- AR083786A1 AR083786A1 ARP110104150A ARP110104150A AR083786A1 AR 083786 A1 AR083786 A1 AR 083786A1 AR P110104150 A ARP110104150 A AR P110104150A AR P110104150 A ARP110104150 A AR P110104150A AR 083786 A1 AR083786 A1 AR 083786A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgf21
- linker
- covalently linked
- antidiabetic compounds
- diabetes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 3
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41071510P | 2010-11-05 | 2010-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083786A1 true AR083786A1 (es) | 2013-03-20 |
Family
ID=45401106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104150A AR083786A1 (es) | 2010-11-05 | 2011-11-07 | Compuestos antidiabeticos |
Country Status (18)
Country | Link |
---|---|
US (1) | US8722622B2 (ja) |
EP (1) | EP2635309A2 (ja) |
JP (1) | JP2014500248A (ja) |
KR (1) | KR20130086623A (ja) |
CN (1) | CN103282055A (ja) |
AR (1) | AR083786A1 (ja) |
AU (1) | AU2011324886A1 (ja) |
BR (1) | BR112013011172A2 (ja) |
CA (1) | CA2815967A1 (ja) |
CO (1) | CO6741158A2 (ja) |
IL (1) | IL225895A0 (ja) |
MX (1) | MX2013005075A (ja) |
PE (1) | PE20140260A1 (ja) |
RU (1) | RU2013118441A (ja) |
SG (1) | SG190082A1 (ja) |
TW (1) | TW201233685A (ja) |
WO (1) | WO2012059873A2 (ja) |
ZA (1) | ZA201303657B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
US10328131B2 (en) | 2014-03-13 | 2019-06-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for regulating pancreatic beta cell function using adipsin |
WO2016014360A1 (en) | 2014-07-24 | 2016-01-28 | Genentech, Inc. | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
WO2016187558A2 (en) | 2015-05-20 | 2016-11-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method to improve neurologic outcomes in temperature managed patients |
RU2752530C2 (ru) | 2015-08-03 | 2021-07-29 | Новартис Аг | Способы лечения расстройств, связанных с fgf21 |
EP3580237A1 (en) | 2017-02-08 | 2019-12-18 | Novartis AG | Fgf21 mimetic antibodies and uses thereof |
BR112020026512A2 (pt) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | Formulações de fgf-21 |
CN113329769A (zh) * | 2018-10-11 | 2021-08-31 | 斯克里普斯研究学院 | 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物 |
MX2022008336A (es) * | 2020-01-08 | 2022-08-08 | Bristol Myers Squibb Co | Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21). |
WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
JP2024516834A (ja) * | 2021-04-30 | 2024-04-17 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Oxm3保存剤、oxm3製剤および調製方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
WO2001027145A1 (en) | 1999-10-08 | 2001-04-19 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
KR20040058229A (ko) | 2001-10-22 | 2004-07-03 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
JP2005519891A (ja) | 2002-01-15 | 2005-07-07 | イーライ・リリー・アンド・カンパニー | 危篤状態の患者における罹病率および死亡率を低下させる方法 |
CA2526169A1 (en) * | 2003-06-12 | 2004-12-23 | Eli Lilly And Company | Fusion proteins |
BRPI0416683A (pt) * | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
US20090111742A1 (en) | 2004-01-26 | 2009-04-30 | Alexei Kharitonenkov | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
CA2557782A1 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
ATE444306T1 (de) | 2004-05-13 | 2009-10-15 | Lilly Co Eli | Fgf-21-fusionsproteine |
JP4809352B2 (ja) | 2004-09-02 | 2011-11-09 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子21の突然変異タンパク質 |
WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080176790A1 (en) * | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子21の突然変異タンパク質 |
WO2006078463A2 (en) | 2005-01-21 | 2006-07-27 | Eli Lilly And Company | Method for treating cardiovascular disease |
CN101287485A (zh) * | 2005-03-03 | 2008-10-15 | 爱尔兰考夫克斯科技有限公司 | 抗血管生成化合物 |
CA2598833A1 (en) | 2005-03-03 | 2006-09-08 | Curt W. Bradshaw | Anti-angiogenic compounds |
KR20120043028A (ko) * | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
JP2010523084A (ja) * | 2007-03-30 | 2010-07-15 | アンブルックス,インコーポレイテッド | 修飾fgf−21ポリペプチド |
US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
EP2488643A4 (en) * | 2009-10-15 | 2013-07-03 | Hoffmann La Roche | CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY |
AU2011277999A1 (en) * | 2010-07-12 | 2013-01-10 | Covx Technologies Ireland Limited | Multifunctional Antibody Conjugates |
-
2011
- 2011-11-02 AU AU2011324886A patent/AU2011324886A1/en not_active Abandoned
- 2011-11-02 PE PE2013000931A patent/PE20140260A1/es not_active Application Discontinuation
- 2011-11-02 JP JP2013537240A patent/JP2014500248A/ja active Pending
- 2011-11-02 BR BR112013011172A patent/BR112013011172A2/pt not_active Application Discontinuation
- 2011-11-02 SG SG2013033378A patent/SG190082A1/en unknown
- 2011-11-02 MX MX2013005075A patent/MX2013005075A/es unknown
- 2011-11-02 WO PCT/IB2011/054874 patent/WO2012059873A2/en active Application Filing
- 2011-11-02 CN CN2011800641240A patent/CN103282055A/zh active Pending
- 2011-11-02 CA CA2815967A patent/CA2815967A1/en not_active Abandoned
- 2011-11-02 RU RU2013118441/15A patent/RU2013118441A/ru not_active Application Discontinuation
- 2011-11-02 EP EP11799823.7A patent/EP2635309A2/en not_active Withdrawn
- 2011-11-02 KR KR1020137014378A patent/KR20130086623A/ko not_active Application Discontinuation
- 2011-11-03 TW TW100140134A patent/TW201233685A/zh unknown
- 2011-11-04 US US13/289,533 patent/US8722622B2/en not_active Expired - Fee Related
- 2011-11-07 AR ARP110104150A patent/AR083786A1/es not_active Application Discontinuation
-
2013
- 2013-04-22 IL IL225895A patent/IL225895A0/en unknown
- 2013-05-03 CO CO13111846A patent/CO6741158A2/es unknown
- 2013-05-20 ZA ZA2013/03657A patent/ZA201303657B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20130086623A (ko) | 2013-08-02 |
WO2012059873A2 (en) | 2012-05-10 |
RU2013118441A (ru) | 2014-12-10 |
CN103282055A (zh) | 2013-09-04 |
US8722622B2 (en) | 2014-05-13 |
JP2014500248A (ja) | 2014-01-09 |
EP2635309A2 (en) | 2013-09-11 |
TW201233685A (en) | 2012-08-16 |
IL225895A0 (en) | 2013-06-27 |
BR112013011172A2 (pt) | 2017-06-06 |
MX2013005075A (es) | 2013-05-28 |
SG190082A1 (en) | 2013-06-28 |
WO2012059873A3 (en) | 2012-06-28 |
CO6741158A2 (es) | 2013-08-30 |
ZA201303657B (en) | 2014-04-30 |
CA2815967A1 (en) | 2012-05-10 |
PE20140260A1 (es) | 2014-03-19 |
US20120282279A1 (en) | 2012-11-08 |
AU2011324886A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083786A1 (es) | Compuestos antidiabeticos | |
CU20110052A7 (es) | Compuestos orgánicos | |
CR11241A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
EA201270242A1 (ru) | Антипролиферативные соединения, их конъюгаты, способы их получения и их применение | |
ECSP11011183A (es) | Compuestos orgánicos | |
ECSP11011184A (es) | Compuestos orgánicos | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
UA111161C2 (uk) | Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування | |
ECSP10010582A (es) | Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
GT200900095A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas. | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
GT200800242A (es) | Derivados biciclicos como inhibidores de cetp | |
NI200900148A (es) | COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A | |
CL2011000134A1 (es) | Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer. | |
HN2010001920A (es) | Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa | |
CR20110413A (es) | Uso como bactericidas de análogos ácidos heteroaromáticos que contienen azufre | |
UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
EA200900090A1 (ru) | Бензиламины, способ их получения и их применение в качестве противовоспалительных средств | |
BR112012006172A2 (pt) | derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia | |
GT200700074A (es) | Fungicidas | |
BRPI1008855B8 (pt) | derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende | |
BR112012013005A2 (pt) | compostos químicos e seu uso como pesticidas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |